Chemoprevention of IBD-Associated Colon Cancer
Chemoprevention of IBD-Associated Colon Cancer
批准号:
7669205
负责人:
Laura P. Hale
金额:
$24.2万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-09-29 至 2011-07-31
关键词:
Adoptive TransferAffectAnimalsAnti-Inflammatory AgentsAnti-inflammatoryApoptosisBiological MarkersBiopsy SpecimenBreedingCD44 geneCarcinogenesis MechanismCell surfaceCellsChemopreventionChronicColitisColonColon CarcinomaColonic NeoplasmsColonoscopyColorectalColorectal CancerCost SavingsCritical PathwaysCytokine SignalingDNADataDevelopmentDietDiseaseDoctor of MedicineDoctor of PhilosophyEnzymesEpitheliumExposure toFamilyFutureGeneral PopulationGeneticHealth ExpendituresHelicobacterHelicobacter hepaticusHistologicHumanIn VitroIncidenceInfectionInflammationInflammation MediatorsInflammatoryInflammatory Bowel DiseasesInterleukin-10InterventionLaboratoriesLeadLesionMediatingModelingMolecularMusNeoplasmsOralOral AdministrationOxidative StressPTGS2 genePatientsPeptide HydrolasesPineapple (Fruit)PiroxicamProductionRelative (related person)Research PersonnelRiskSavingsScreening procedureSeveritiesSignal TransductionStagingT-Cell ActivationT-Cell ProliferationT-LymphocyteTP53 geneTestingTherapeutic EffectTissuesUlcerative Colitisaspergillopepsin IIbasecancer riskcarcinogenesiscytokinedesignin vivomouse modelnovelpatient populationpreventprogramsrepairedstemsuccess
中文摘要
描述(由申请人提供):炎症性肠病(IBD)患者患结直肠癌的风险比一般人群高20 - 30倍。这种增加的癌症风险归因于炎症介质引起的氧化应激引起的遗传损伤,以及粘膜修复过程中结肠上皮的增殖。ibd相关的肿瘤可以通过结肠镜筛查在早期发现,有可能治愈。然而,安全有效的预防结肠癌的新策略将对IBD患者大有裨益,并最终导致相当大的成本节约。最近的动物研究表明,抑制T细胞介导的结肠炎症可以降低结肠癌的风险。我们的研究表明,口服菠萝蛋白酶(一种从菠萝中提取的蛋白酶混合物)可显著降低il -10缺陷小鼠自发性结肠炎的发生率和已建立的T细胞介导结肠炎的严重程度。我们实验室和其他实验室先前的体外研究表明,菠萝蛋白酶可以降低T细胞增殖、信号转导和细胞因子的产生。其体外和体内的抗炎作用取决于其蛋白水解活性。本研究旨在验证菠萝蛋白酶治疗通过减少T细胞介导的炎症引起的遗传损伤来降低ibd相关结肠癌风险的假设。具体目的是确定菠萝蛋白酶对慢性T细胞介导的结肠炎小鼠炎症和结肠肿瘤发展的影响。炎症的严重程度和结肠肿瘤的发生率将通过组织学来确定。将确定炎症相关的DNA氧化损伤以及治疗对信号转导和关键生物标志物表达的相关影响,以直接评估菠萝蛋白酶对炎症和结直肠癌发生关键途径的影响。这些研究将进一步阐明新的干预措施预防IBD相关结肠癌的机制,为IBD患者及其家属提供巨大的利益。
英文摘要
DESCRIPTION (provided by applicant): Patients with inflammatory bowel disease (IBD) have a 20 to 30-fold increased risk of colorectal cancer relative to the general population. This increased cancer risk has been attributed to genetic damage from oxidative stress caused by inflammatory mediators combined with the proliferation of colonic epithelium during mucosal repair. IBD-associated neoplasia can be detected at an early, potentially curable stage by colonoscopic screening. However, safe and effective new strategies for preventing colon cancer would be of great benefit to IBD patients and should ultimately lead to considerable cost savings. Recent animal studies have shown that inhibiting T cell-mediated colon inflammation can decrease the risk of colon cancer. Our studies show that oral administration of bromelain, a proteinase mixture derived from pineapple, significantly decreases both the incidence of spontaneous colitis and the severity of established T cell-mediated colitis in IL-10-deficient mice. Previous in vitro studies by our laboratory and others have shown that bromelain decreases T cell proliferation, signal transduction, and cytokine production. Its anti-inflammatory effects in vitro and in vivo depend on its proteolytic activity. This proposal is designed to test the hypothesis that bromelain treatment will decrease the risk of IBD-associated colon cancer by decreasing the genetic damage caused by T cell-mediated inflammation. The specific aims will determine the effect of bromelain on inflammation and development of colon neoplasia in mice with chronic T cell-mediated colitis. The severity of inflammation and the incidence of colonic neoplasia will be determined histologically. Inflammation-associated oxidative lesions in DNA and treatment-related effects on signal transduction and critical biomarker expression will be determined to directly assess effects of bromelain on pathways critical to inflammation and colorectal carcinogenesis. The proposed studies will further elucidate mechanisms that can lead to novel interventions to prevent IBD-associated colon cancers, providing great benefit to IBD patients and their families.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Core C: Human Thymus Core
-
批准号:10251296
-
项目类别:
-
资助金额:$36.59万
-
财政年份:2020
-
负责人:Laura P. Hale
-
依托单位:
Core C: Human Thymus Core
-
批准号:10689280
-
项目类别:
-
资助金额:$48.93万
-
财政年份:2020
-
负责人:Laura P. Hale
-
依托单位:
Core C: Human Thymus Core
-
批准号:10022936
-
项目类别:
-
资助金额:$38.1万
-
财政年份:2020
-
负责人:Laura P. Hale
-
依托单位:
Core C: Human Thymus Core
-
批准号:10470929
-
项目类别:
-
资助金额:$36.55万
-
财政年份:2020
-
负责人:Laura P. Hale
-
依托单位:
Human Target Verification and Thymic Function Core
-
批准号:10553991
-
项目类别:
-
资助金额:$18.32万
-
财政年份:2017
-
负责人:Laura P. Hale
-
依托单位:
Mechanisms Underlying Colorectal Cancer Risk in IBD (PQ6)
-
批准号:8543669
-
项目类别:
-
资助金额:$16.05万
-
财政年份:2012
-
负责人:Laura P. Hale
-
依托单位:
Mechanisms Underlying Colorectal Cancer Risk in IBD (PQ6)
-
批准号:8370935
-
项目类别:
-
资助金额:$20.49万
-
财政年份:2012
-
负责人:Laura P. Hale
-
依托单位:
Mast Cells and IBD Pathogenesis
-
批准号:7128496
-
项目类别:
-
资助金额:$23.33万
-
财政年份:2006
-
负责人:Laura P. Hale
-
依托单位:
Chemoprevention of IBD-Associated Colon Cancer
-
批准号:7195393
-
项目类别:
-
资助金额:$24.85万
-
财政年份:2006
-
负责人:Laura P. Hale
-
依托单位:
Chemoprevention of IBD-Associated Colon Cancer
-
批准号:7897692
-
项目类别:
-
资助金额:$24.2万
-
财政年份:2006
-
负责人:Laura P. Hale
-
依托单位:
Chemoprevention of IBD-Associated Colon Cancer
-
批准号:7496973
-
项目类别:
-
资助金额:$24.2万
-
财政年份:2006
-
负责人:Laura P. Hale
-
依托单位:
Mast Cells and IBD Pathogenesis
-
批准号:7282740
-
项目类别:
-
资助金额:$18.93万
-
财政年份:2006
-
负责人:Laura P. Hale
-
依托单位:
Chemoprevention of IBD-Associated Colon Cancer
-
批准号:7295950
-
项目类别:
-
资助金额:$24.2万
-
财政年份:2006
-
负责人:Laura P. Hale
-
依托单位:
Bromelain Proteinase Activity in IBD
-
批准号:7046140
-
项目类别:
-
资助金额:$17.37万
-
财政年份:2005
-
负责人:Laura P. Hale
-
依托单位:
Bromelain Proteinase Activity in IBD
-
批准号:6898569
-
项目类别:
-
资助金额:$19.14万
-
财政年份:2005
-
负责人:Laura P. Hale
-
依托单位:
Novel Oral Adjuvant for Dental Vaccines
-
批准号:6859474
-
项目类别:
-
资助金额:$19.25万
-
财政年份:2004
-
负责人:Laura P. Hale
-
依托单位:
Bromelain as a Biologically-Based Therapy for IBD
-
批准号:6947937
-
项目类别:
-
资助金额:$19.25万
-
财政年份:2004
-
负责人:Laura P. Hale
-
依托单位:
Bromelain as a Biologically-Based Therapy for IBD
-
批准号:6804195
-
项目类别:
-
资助金额:$19.25万
-
财政年份:2004
-
负责人:Laura P. Hale
-
依托单位:
Novel Oral Adjuvant for Dental Vaccines
-
批准号:6954192
-
项目类别:
-
资助金额:$19.25万
-
财政年份:2004
-
负责人:Laura P. Hale
-
依托单位:
MECHANISMS OF AGE RELATED THYMIC INVOLUTION
-
批准号:6077834
-
项目类别:
-
资助金额:$23.1万
-
财政年份:1998
-
负责人:Laura P. Hale
-
依托单位:
海外基金